{"links":{"feed":"https://www.erudio.com/reports/herthena-breast04-nct07060807/feed.json","html":"https://www.erudio.com/reports/herthena-breast04-nct07060807","json":"https://www.erudio.com/reports/herthena-breast04-nct07060807.json","markdown":"https://www.erudio.com/reports/herthena-breast04-nct07060807.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"herthena-breast04-nct07060807"}},"request":"https://www.erudio.com/contact?report=herthena-breast04-nct07060807"},"offer":{"cited_clinicians":4,"cited_commentary_sources":5,"verified_hcp_statements":27,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":5},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"herthena-breast04-nct07060807"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=herthena-breast04-nct07060807","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/herthena-breast04-nct07060807","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 27 verified statements · 13 from 4 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T13:15:22.032657Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":1},"aspects":[{"claim_count":2,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Progression Free Survival (PFS)"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":1,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":2,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":1,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":1,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":2,"title":"Endocrine-treatment boundary and the case-specific IHC 0 ADC judgment"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":2,"title":"Molecular work-up at progression"},{"claim_count":7,"coverage":"discussed","id":"A3","source_count":2,"title":"Second-line options, sequencing and the prognosis question after early progression"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":2,"title":"Earlier HER3-DXd evidence informing phase 3 expectations"},{"claim_count":2,"coverage":"discussed","id":"A5","source_count":1,"title":"Participation, possible access and patient communication"}],"counts":{"beyond_population_findings":5,"beyond_population_statements":20,"cited_clinicians":4,"cited_clinicians_by_role":{"physician":1,"physician, Hematology and oncology":1,"physician, Medical oncology":2},"cited_physicians":4,"cited_sources":5,"claims_by_expression_type":{"comparison":2,"interpretation":2,"opinion":8,"primary_context":3,"question":2,"restatement":4,"uncertainty":1,"unspecified":5},"claims_by_kind":{"source_observation":27},"clinician_statements":13,"evidence_units":27,"findings":6,"organisational_accounts":1,"people_cited":5,"people_identity_verified":5,"people_total":5,"screened_sources":28,"verified_claims":27},"findings_index":[{"cited_clinicians":0,"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":1},"limitations":3,"links":{"context":5,"support":5},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"Entry: a speaker sees possible access & contribution, no assured survival","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-7e67202062041e2c9754"],"clause":"no assured survival","holders":0},"cited_claim_ids":["claim-7e67202062041e2c9754"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"5 statements in 1 source, a podcast or video","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":1,"id":"F1","population":"beyond","structure":{"claims":1,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":0},"limitations":2,"links":{"context":1,"support":1},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"HERTHENA-Breast04: why a clinician sees it as confirmatory after ICARUS-B01","title_holders":{"cited_claim_ids":["claim-b12512f1e2dc5707cac0"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"1 statement from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician"},{"cited_clinicians":1,"id":"F3","population":"beyond","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":4},"limitations":3,"links":{"context":6,"support":7},"ma_question":true,"named_voices":1,"passages":9,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Endocrine-sensitive case: a clinician defers chemo but excludes Trastuzumab deruxtecan","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-41026d00d8ad55468281","claim-b3b3383e07cdc8bdbba9"],"clause":"exclude Trastuzumab deruxtecan","holders":1},"cited_claim_ids":["claim-bbd0f0c7819cd02c22ed","claim-19487f817fa750199f86"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"7 statements from 1 speaker in 3 sources, 1 of them a podcast or video","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “exclude Trastuzumab deruxtecan”"},{"cited_clinicians":1,"id":"F4","population":"beyond","structure":{"claims":3,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":2},"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":1,"passages":3,"sources":2,"sources_by_kind":{"commentary":2}},"title":"1L progression: what speakers say","evidence_line":"3 statements from 1 speaker in 2 sources"},{"cited_clinicians":3,"id":"F5","population":"beyond","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":2,"views":3},"limitations":3,"links":{"context":2,"support":8},"ma_question":true,"named_voices":3,"passages":8,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Second line: a clinician sees options, no known order; one queries prognosis","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-aa9467649312ad8b6364","claim-5a6bd1610a299111fc5e"],"clause":"one queries prognosis","holders":1},"cited_claim_ids":["claim-79b4cc7bfcb8b19633bc","claim-25c23cff6c4199a9e8b2","claim-6876a5e25f5c696228e5"],"clinicians":true,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"8 statements from 3 speakers in 2 sources","holder_line":"1 of the 3 named speakers in this finding holds this view, a confirmed clinician; 1 of the 3 holds its caveat, “one queries prognosis”"},{"cited_clinicians":0,"id":"F6","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":0},"limitations":2,"links":{"context":1,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"ICARUS-BREAST01: what a speaker highlights in the translational work","title_holders":{"cited_claim_ids":["claim-971f0924a27f37ee0bd4","claim-6bf3642f664254394b4f"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"2 statements from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One patient-information video distinguishes possible participation benefits from the survival question"},{"id":"section-2","level":2,"title":"Beyond the trial population"},{"id":"section-3","level":3,"title":"One X account uses earlier activity to frame HERTHENA-Breast04 as confirmatory"},{"id":"section-4","level":3,"title":"Two accounts would defer capecitabine or sacituzumab in an endocrine-sensitive case"},{"id":"section-5","level":3,"title":"Two accounts favor molecular reassessment, with conditional assay trade-offs"},{"id":"section-6","level":3,"title":"One X account welcomes options while leaving sequence unresolved; another asks about disease tempo"},{"id":"section-7","level":3,"title":"Whether the earlier ICARUS-BREAST01 work could be a breakthrough"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":2}],"id":"T1","label":"Primary endpoint: Progression Free Survival (PFS)"},{"findings":[{"id":"F2","shared_claims":2}],"id":"T2","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":2}],"id":"T6","label":"Safety and tolerability"},{"findings":[],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T13:15:22.032657Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T13:42:22Z","record_hash":"09c13d40bb328519afcfb3e0a017b25327580fde2f3303a235f169a610fea5ca","release_hash":"637ebb1e5136d9b2756d6ceca3c5ed86c880f1c16c7f8ad82b276d3da55bd06e","report_id":"erudio-nct07060807","run_id":"65b2263f-95e8-447e-b0b8-a685b019de46","schema_version":"5.0","slug":"herthena-breast04-nct07060807","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A medical oncologist viewed HERTHENA-Breast04 as a test of an ICARUS-B01 signal they considered comparable to T-DXd; that comparison rested on single-arm evidence. Commentary on the trial itself is limited. In the broader post-CDK4/6 discussion, a hematology-oncology physician would defer capecitabine or sacituzumab in a case they did not consider endocrine resistant. The sources reviewed for this edition contain no publication reporting the trial’s outcomes.","examples":[],"meta_description":"28 sources screened · 27 verified statements (13 from clinicians verified by NPI or staff page) from 5 sources · 6 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T13:42:22Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":28},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","4 passages in 3 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","70 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 35 sources about other trials or topics are not included.","These source-specific statements do not establish the prevalence of a view among HCPs or a clinical consensus.","Some passages in the case discussions and patient-information video were not fully assessed, and discussion without trial names or identifiers may be missing.","No full protocol or publication reporting HERTHENA-Breast04 outcomes was included in the sources reviewed for this edition; earlier phase 2 evidence and planned assessments must not be read as phase 3 findings.","Drug-label information was incomplete, including no exact label identified for Patritumab deruxtecan or Nab-paclitaxel. The report does not independently resolve labeled use or eligibility.","Parallel X and Bluesky content and reposts should not be counted as independent clinical agreement.","The individual author behind a speaker is not established. The patient-information video's statements are not attributable to a proven named clinician."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":3,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":5},"count":5,"evidence_window":{"end":"2026-02-11","start":"2025-09-04"},"retrieval_snapshot":"2026-11-19T12:18:27.481923Z","timeline":[{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":2,"week":"2025-W43"},{"count":1,"week":"2026-W07"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07060807:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07060807:context","quote_policy":"short_quote_link_out"},{"id":"openfda:e4be6cbf-72b9-4f7f-9b1b-459b2d35961a:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-37ke4hieqksucnwp4a3htxwj-3lxhdmf2bdb2z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-4w7jzkpdswrg7tf4azxu3gsc-3lxewotx4wr2a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3lxevxyvvlg2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mt4db4uc626ds6iiilf56zy6-3m3pdz235bs2c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-nfy3bfl5dt6xfyuuzb7pmtyo-3m3qmqicwds2w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-o6ggjvnj4ze3mnrpnv5oravg-3lxiqy2oynh2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ynbscw644x7ovpgse3wx4qar-3m7gp5csmw42i","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960658752081735805:4e732de3-71e3-45b5-bbb5-70a833b8c782","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960658786630168702:fce50717-84d3-4621-b4d7-a5cafb847555","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960659060384055389:b018c7ae-8a5b-433d-a97d-8eeb06cdf6bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960660079314657473:083ebc40-7b65-4ea3-a3d1-af06958ace4a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960660211263263091:7b70defd-cd99-4879-97d9-703d09626b0e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960661268760494344:eeb9190f-7395-4768-a7f5-86a051acfefb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960663589242417296:54804457-ca5c-4c74-b758-ee87105e8da4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960677456731660475:c867f754-f64f-4d3e-b5ee-4d2eb09eb9fb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1960974062983041113:f2b26022-0c86-4f30-a796-2fc7b4ceda6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1961013479969521868:2ecd820f-dbd7-4df9-b807-e0c28056d52a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1961400473174643037:955f540f-8029-438b-8132-e9fa0df01962","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1963545587057361026:0930a37d-ec8f-48d2-a9ec-89b5203f5b1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964975168608239800:17423899-b3e9-4637-b4ec-2c0ebd4bd49a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980242586733293707:608d7979-b910-4c5c-95a3-8f2c60967ebc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051960254225682870:0a27a2a4-6f50-46ca-bd0b-1f27afc2b7e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2072772298122113386:02ed324f-ab4a-450c-91eb-39cbc4d16eb8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113605272119951477:5bb4d062-4b9e-4381-89fd-59ca574f96c2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113605707849175344:9775db13-c6eb-490a-b181-3651d1411df5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113606199530700950:c995a346-6982-4b07-bc5d-ed97509a4955","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113664656011063424:48cc0507-aae7-4878-bf74-56d00e5f7cfb","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:NO0UHwimxEU","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":7,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":20,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":28},"count":28,"evidence_window":{"end":"2026-10-23","start":"2025-08-27"},"retrieval_snapshot":"2026-11-19T12:18:27.481923Z","timeline":[{"count":15,"week":"2025-W35"},{"count":1,"week":"2025-W36"},{"count":1,"week":"2025-W37"},{"count":3,"week":"2025-W43"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W19"},{"count":1,"week":"2026-W27"},{"count":4,"week":"2026-W43"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":8,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":5}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"patritumab deruxtecan","slug":"patritumab-deruxtecan"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Abraxane"],"label":"nab-paclitaxel","slug":"nab-paclitaxel"},{"brand_names":["Xeloda"],"label":"capecitabine","slug":"capecitabine"},{"brand_names":["Doxil","Caelyx"],"label":"pegylated liposomal doxorubicin","slug":"pegylated-liposomal-doxorubicin"},{"brand_names":["Enhertu"],"label":"trastuzumab deruxtecan","slug":"trastuzumab-deruxtecan"},{"reason":"Unmapped registry intervention: rescue medication","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: Breast Neoplasms","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Breast cancer","slug":"breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"HERTHENA-Breast04","aliases":["HERTHENA-Breast04","MK-1022-016","A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)."],"brief_title":"A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)","collaborators":["Daiichi Sankyo"],"conditions":["Breast Neoplasms"],"display_condition":"hormone receptor-positive, HER2-negative unresectable locally advanced or metastatic breast cancer","display_interventions":[["patritumab deruxtecan"]],"enrollment":{"count":1000,"type":"ESTIMATED"},"interventions":[{"name":"Patritumab deruxtecan","synonyms":["MK-1022","HER3-DXd","U3-1402"],"type":"BIOLOGICAL"},{"name":"Paclitaxel","synonyms":["TAXOL®","ONXAL®"],"type":"DRUG"},{"name":"Nab-paclitaxel","synonyms":["Abraxane®"],"type":"DRUG"},{"name":"Capecitabine","synonyms":["XELODA®"],"type":"DRUG"},{"name":"Pegylated liposomal doxorubicin","synonyms":["Doxil®"],"type":"DRUG"},{"name":"Trastuzumab deruxtecan","synonyms":["T-DXd","Enhertu®"],"type":"BIOLOGICAL"},{"name":"Rescue Medication","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07060807","official_title":"An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2033-07-14","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by blinded independent central review (BICR). Per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.","measure":"Progression Free Survival (PFS)","timeFrame":"Up to approximately 45 months"},{"description":"OS is the length of time from when the participant starts treatment until death from any cause.","measure":"Overall Survival (OS)","timeFrame":"Up to approximately 85 months"}],"registered_date":{"date":"2025-07-11","type":"ACTUAL"},"registry_last_updated":"2026-11-03","registry_url":"https://clinicaltrials.gov/study/NCT07060807","short_name":"HERTHENA-Breast04","short_name_basis":"canonical_name","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2025-07-21","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"1022-016","type":"sponsor_study_id"},{"domain":"UTN","id":"U1111-1317-5490","type":"registry"},{"domain":"EU CT","id":"2025-520582-51-00","type":"registry"},{"domain":"Japan Registry of Clinical Trial (jRCT)","id":"jRCT2031250297","type":"registry"}],"study_type":"INTERVENTIONAL"}}}